AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (Currently Amended): An aminophenoxyacetamide derivative represented by the following formula (I):



(I)

wherein:

R^1, R^2, R^3 and R^4 are, independent from each other, hydrogen atom or lower alkyl group;

R^5 R^6 $R^7$and $R^8$are, independent from each other, hydrogen atom or lower alkyl group;

E^1 is group $-NR^9-$ (in which, R^9 is hydrogen atom or lower alkyl group);

E^2 is oxygen atom or group $-NR^{10}-$ (in which, R^{10} is hydrogen atom or lower alkyl group which may be substituted);

Q is a group of -X-Y-Q', wherein X is a connecting bond, lower alkyl group, lower alkenyl group, or lower alkynyl group; Y is a connecting bond, or a group selected from the groups consisting of C=O, C(=O)NH, NHC(=O), -O-, -S-, CH(OH), -O-CH(OH)- and $-O-CH_2-CH(OH)-$, in which hydrogen atom of amido group may be

substituted with lower alkyl group; and Q' is hydrogen atom or a cyclic group selected from the ~~groups~~ group consisting of ~~aryl group, heteroaryl group, saturated or unsaturated cyclic hydrocarbon group~~ phenyl group, pyridily group, quinolyl group, isoquinolyl group, benzothiazole group, benzimidazole group, cyclic hydrocarbon group, and saturated or unsaturated heterocyclic group, wherein one or more of the hydrogen atoms in the cyclic group of Q' may be substituted;

either in the case that ~~X and Y are both connecting bond then Q' is not hydrogen atom; or in the case that one of X and Y is other than connecting bond then~~ E^2 is the group ~~-O- and~~ -NR^{10}- then X and Y are both connecting bond and Q' is not hydrogen atom; or in the case that E^2 is the group -O- then all of the groups R^1, R^2, R^3 and R^4 are ~~not hydrogen atom~~ methyl group; or a pharmaceutically acceptable salt thereof.

Claim 2 (Previously Presented): The aminophenoxyacetamide derivative of formula (I) claimed in claim 1, wherein X and Y are both connecting bond; or pharmaceutically acceptable salts thereof.

Claim 3 (Previously Presented): The aminophenoxyacetamide derivative of formula (I) claimed in claim 1, wherein one of X and Y is other than connecting bond and E^2 is the group -O- and all of the groups of R^1, R^2, R^3 and R^4 are other than hydrogen atom, wherein X, Y, R^1, R^2, R^3 and R^4 are the same as defined above in claim 1; or pharmaceutically acceptable salts thereof.

Claims 4-21 (Canceled).

Claim 22 (Previously Presented): A composition comprising an aminophenoxyacetamide derivative or a pharmaceutically acceptable salt thereof represented by the formula (I) in claim 1 as an active ingredient.

Claim 23 (Previously Presented): A composition comprising an aminophenoxyacetamide derivative or a pharmaceutically acceptable salt thereof represented by the formula (I) in claim 2 as an active ingredient.

Claim 24 (Previousy Presented): A composition comprising an aminophenoxyacetamide derivative or a pharmaceutically acceptable salt thereof represented by the formula (I) in claim 3 as an active ingredient.

Claim 25 (Withdrawn): A method for inducing the production of CalbindinD-28K wherein said method comprises administering to a patient a composition according to claim 22.

Claim 26 (Withdrawn): A method for inducing the production of CalbindinD-28K wherein said method comprises administering to a patient a composition according to claim 23.

Claim 27 (Withdrawn): method for inducing the production of CalbindinD-28K wherein said method comprises administering to a patient a composition according to claim 24.

Claim 28 (Withdrawn): A method for improving or treating cerebral function and/or organic function disorders wherein said method comprises administering to a patient a composition according to claim 22.

Claim 29 (Withdrawn): The method of claim 28, wherein said cerebral function disorders are caused by ischemic disorders.

Claim 30 (Withdrawn): The method of claim 29, wherein said ischemic disorders are selected from the group consisting of cerebral infarction, intracerebral hemorrhage and cerebral arteriosclerosis.

Claim 31 (Withdrawn): The method of claim 28, wherein said organic function disorders are selcted from the group consisting of senile dementia, cerebral injury, cerebral operation, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Claim 32 (Withdrawn): A method for improving or treating cerebral function and/or organic function disorders wherein said method comprises administering to a patient a composition according to claim 23.

Claim 33 (Withdrawn): The method of claim 32, wherein said cerebral function disorders are caused by ischemic disorders.

Claim 34 (Withdrawn): The method of claim 33, wherein said ischemic disorders are selected from the group consisting of cerebral infarction, intracerebral hemorrhage and cerebral arteriosclerosis.

Claim 35 (Withdrawn): The method of claim 32, wherein said organic function disorders are selected from the group consisting of senile dementia, cerebral injury, cerebral operation, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Claim 36 (Withdrawn): A method for improving or treating cerebral function and/or organic function disorders wherein said method comprises administering to a patient a composition according to claim 24.

Claim 37 (Withdrawn): The method of claim 36, wherein said cerebral function disorders are caused by ischemic disorders.

Claim 38 (Withdrawn): The method of claim 37, wherein said ischemic disorders are selected from the group consisting of cerebral infarction, intracerebral hemorrhage and cerebral arteriosclerosis.

Claim 39 (Withdrawn): The method of claim 36, wherein said organic function disorders are selcted from the group consisting of senile dementia, cerebral injury, cerebral operation, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Claim 40 (Withdrawn): A method for selecting a neuroprotective compound, wherein said method comprises evaluating the activation of receptors for various kinds of physiologically active substances and the phosphorylation of the FGF receptor caused by the induction of CalbindinD-28k production.

Claim 41 (Withdrawn): The method for selecting a neuroprotective compound according to claim 40, wherein said method comprises evaluating the autophosphorylation of the FGF receptor.

Claim 42 (Withdrawn): The method for selecting a neuroprotective compound according to claim 40, wherein said method is performed by evaluating for neuroprotective effect of the physiologically active substance against glutamate-induced neurodegeneration together with one or more of the following tests (i)-(iii):

(i) evaluating for antagonism against the neuroprotective effect of the physiologically active substance by treatment with MTA (5-deoxy-5-methyl-thioadenosine), which inhibits autophosphorylation of the FGF receptor, and by treatment with inhibitors of various physiologically active substance receptors, to determine if the neuroprotective effect is due to autophosphorylation of receptors of the FGF receptor;

(ii) evaluating the CalbindinD-28k inducing effect of the physiologically active substance; or

(iv) confirming that the neuroprotective effect of the physiologically active substance is due to its inducing CalbindinD-28k production, by treating with the

antisense oligonucleotide of CalbindinD-28k and determining if CalbindinD-28k production is antagonized.

Claim 43 (Withdrawn): The method according to claim 18, wherein said physiological active substance receptors are selected from the group consisting of receptors for neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), brain-derived neurotrophic factor (BDNF), insulin-like growth factor-I/II (IGF-I/II), platelet-derived growth factor (PDGF), and estrogen.

Claim 44 (Withdrawn): A neuroprotective compound selected by the method according to claim 40.

Claim 45 (Withdrawn): A composition comprising a neuroprotective compound according to claim 44.

Claim 46 (Withdrawn): A method of treating or improving cerebral functional disorders and/or cerebral organic disorders, wherein said method comprises administering the composition according to claim 45 to a patient in need thereof.

Claim 47 (Withdrawn): The method according to claim 46, wherein said cerebral functional disorders are caused by ischemic disorders.

Claim 48 (Withdrawn): The method according to claim 47, wherein said ischemic disorders are selected from the group consisting of cerebral infarction, intracerebral hemorrhage and cerebral arteriosclerosis.

Claim 49 (Withdrawn): The method according to claim 46, wherein said cerebral organic disorders are selected from the group consisting of senile dementia, cerebral injury, cerebral operation, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Claim 50 (New): The aminophyenoxyacetamide derivative of formula (I) claimed in claim 1, where Q' is a cyclic hydrocarbon group and said cyclic hydrocarbon group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

Claim 51 (New): The aminophenoxyacetamide derivative of formula (I) claimed in claim 1, wherein Q' is an unsaturated or saturated heterocyclic group and said unsaturated or saturated heterocyclic group is morpholinyl.